<unk> (oral) is a topoisomerase inhibitor that is FDA approved for the treatment of patients with relapsed small cell lung cancer. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include neutropenia, anemia, and thrombocytopenia. The most common non-hematologic adverse reactions (all grades) were nausea,diarrhea, vomiting, alopecia, and fatigue.
Topotecan 
Ifosfamide
Mafosfamide
Zorubicin
Etoposide 
Vincristine sulfate
Idoxuridine
Semustine